Perspective Therapeutics (CATX) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Perspective Therapeutics (CATX) over the last 16 years, with Q2 2025 value amounting to $514000.0.
- Perspective Therapeutics' Income towards Parent Company rose 20489.8% to $514000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $514000.0, marking a year-over-year increase of 10838.23%. This contributed to the annual value of -$949000.0 for FY2024, which is 8951.73% up from last year.
- Per Perspective Therapeutics' latest filing, its Income towards Parent Company stood at $514000.0 for Q2 2025, which was up 20489.8% from -$490000.0 recorded in Q2 2024.
- In the past 5 years, Perspective Therapeutics' Income towards Parent Company registered a high of $1.3 million during Q2 2021, and its lowest value of -$5.2 million during Q4 2023.
- Its 5-year average for Income towards Parent Company is -$1.5 million, with a median of -$1.5 million in 2023.
- As far as peak fluctuations go, Perspective Therapeutics' Income towards Parent Company soared by 21329.97% in 2021, and later crashed by 25438.34% in 2022.
- Quarter analysis of 5 years shows Perspective Therapeutics' Income towards Parent Company stood at -$1.6 million in 2021, then plummeted by 41.83% to -$2.3 million in 2022, then plummeted by 127.82% to -$5.2 million in 2023, then soared by 90.55% to -$490000.0 in 2024, then soared by 204.9% to $514000.0 in 2025.
- Its Income towards Parent Company was $514000.0 in Q2 2025, compared to -$490000.0 in Q2 2024 and -$459000.0 in Q1 2024.